Tech Company Financing Transactions
BlueWillow Biologics Funding Round
BlueWillow Biologics closed a $11 million Series C investment round on 11/29/2012. Investors included Merck Capital Ventures, Perseus and Venture Investors.
Transaction Overview
Company Name
Announced On
11/29/2012
Transaction Type
Venture Equity
Amount
$11,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the company's development programs for herpes labialis (cold sores), cystic fibrosis and nanoemulsion-based vaccines for respiratory syncytial virus (RSV) and genital herpes (HSV2).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2311 Green Rd.
Ann Arbor, MI 48105
USA
Ann Arbor, MI 48105
USA
Phone
Website
Email Address
Not Recorded
Overview
BlueWillow Biologics is a privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines, based on its patented nanotechnology platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Peralta
VP - Bus. Development
David Muth
VP - R & D
Ali Fattom
Browse more venture capital transactions:
Prev: 11/29/2012: iSchool Campus venture capital transaction
Next: 11/29/2012: CV Ingenuity venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to record funding rounds that are announced publicly. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs